<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/708185C9-6CDB-43AE-87D5-DD3D71666651"><gtr:id>708185C9-6CDB-43AE-87D5-DD3D71666651</gtr:id><gtr:firstName>J</gtr:firstName><gtr:surname>Serwanga</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U950080939"><gtr:id>FA7C3BF6-5993-4430-9090-D94350BA6F7E</gtr:id><gtr:title>Basic Science Programme / DART Immunology Substudy Project</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U950080939</gtr:grantReference><gtr:abstractText>It has been suggested that patients who achieve viral suppression due to antiretroviral treatment (ART) may differ with regards to the type and quality of the immune response to HIV that they are able to regain after some time on ART, depending on whether they are treated continuously or undergo structured treatment interruptions (STIs). It has also been proposed that the immune system of a patient may achieve a higher level of competence if HIV is not totally suppressed. The DART trial provided an opportunity to study this question: This trial has a study component aiming to investigate the clinical effectiveness of STIs as compared to that of continuous treatment (CT). Whilst this component of the DART Trial was terminated early in 2006 because CT showed better clinical results than STI, the immunological research component continues using specimens obtained from patients who formerly participated in this trial component.</gtr:abstractText><gtr:technicalSummary>Purpose: To compare the HIV-specific immune reconstitution following exposure to antiretroviral therapy (ART) in patients who received ART through structured treatment interruption (STI) with that in participants who received continuous treatment (CT). This research will allow to establish whether the immune system of a patient on ART may achieve a higher level of competence if HIV is not totally suppressed.||Methods: Study participants were recruited from the DART Trial study clinic in Entebbe (see separate abstract). A sub-group of patients of this trial were randomized to either STI or CT once their immune status has substantially approved. At baseline, before patients started ART, HIV-induced CD8 perforin and interferon gamma (IFN- ) release to vpu, vpr, tat, rev, vif, and nef HIV peptide pools was evaluated. Staphylococcal enterotoxin B (SEB) were used for positive control tests while unstimulated specimens were used to evaluate pre-existing cytokine release. Subsequently, immune responses are evaluated at three-monthly intervals using intracellular cytokine staining assay. Immune responses were correlated with viral load, CD4 counts and clinical observations and compared between individuals on STI and on CT.</gtr:technicalSummary><gtr:fund><gtr:end>2009-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>656394</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dart immunology substudy</gtr:description><gtr:id>697CDEF7-767C-4823-B298-38985CE24621</gtr:id><gtr:impact>A paper was published</gtr:impact><gtr:outcomeId>5E57F16E133-1</gtr:outcomeId><gtr:partnerContribution>Training other capacity building and publications</gtr:partnerContribution><gtr:piContribution>Our team has processed the samples and performed the immunological assays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lack of benefit of structured treatment on immune response</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EB68EFDC-B0FB-42A6-90AB-DE6228401B3E</gtr:id><gtr:impact>The interruption of ARV treatment in HIV patients is not encouraged</gtr:impact><gtr:outcomeId>ECRoDq1Pp9n</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CC071C55-D55D-41C1-86CC-5955FAA6C159</gtr:id><gtr:title>CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells &amp;lt;200 Cell/?L: The DART Trial STI Substudy.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>cSkFBdCp1at</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U950080939</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>